Treatment for serious eye disease approved in Scotland
Ella Day | June 12, 2025 | News story | Market Access, Marketing Services, Research and Development, Sales and Marketing | LYTENAVA, Opthalmology, Scottish Medicines Consortium, clinical programme, european union, eye disease, market approval, strategic partnership, united kingdom, wet age-related macular degeneration
Outlook Therapeutics has announced the Scottish Medicines Consortium (SMC) approval of Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD). Lytenava is the first and only licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and UK.
The SMC recommendation follows news of Lytenava becoming commercially available in the UK earlier this month. Both decisions were influenced by Outlook’s AMD clinical programme, including three clinical trials, as well as supporting studies and peer-reviewed literature.
“This approval ensures that patients in Scotland will have access to an additional treatment option. Our focus now is to work closely with healthcare providers to ensure a smooth rollout and to continue our mission of advancing healthcare solutions,” commented Jedd Comiskey, senior vice president, head of Europe at Outlook.
To support the commercial launch of Lytenava, Outlook has partnered with Cencora (formerly AmerisourceBergen), a US-based pharma solutions company. This collaboration is designed to enhance the efficiency and accessibility of rollout.
Wet AMD is an eye condition characterised by the growth of abnormal blood vessels behind the retina, which damage nearby cells, leading to vision loss.
Lytenava is a recombinant human monoclonal antibody and Outlook’s leading therapy for retina diseases. The company intends for the treatment to enter the US market next.
Ella Day
12/6/25
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment
Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in …
